GLOBAL BLOOD THERAPEUTICS Stock News

These companies just raised significant cash to advance promising drug pipelines.

In a report issued on April 20, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals (SNDX), with a price target of $16.00. The

Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.

Brokerages predict that Global Blood Therapeutics Inc (NASDAQ:GBT) will report earnings of ($1.48) per share for the current quarter, Zacks reports. Eight analysts have issued estimates for Global Blo

Wall Street analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to announce $3.40 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for G

Global Blood Therapeutics provided a quarterly update recently. In it, novel sickle cell disease drug, Oxbryta, netted a mere $2M in revenue. On the clinical fr

Frontier Capital Management Co. LLC trimmed its stake in Global Blood Therapeutics Inc (NASDAQ:GBT) by 60.6% in the 1st quarter, according to the company in its most recent filing with the Securities

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR), Theratechnologies (THTX) and Galapagos (GLPG). Danaher

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Unity Biotechnology (UBX) today and set a price target of $13.00. The company's shares

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Unity Biotechnology (UBX – Research Report) today and set a

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Immunomedics (IMMU), with a price target of $22.00. The

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Immunomedics ( IMMU – Research Report ), with a price target of $22.00 . The company’s shares closed la

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics (DNLI), with a price target of $28.00. The

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics ( DNLI – Research Report ), with a price target of $28.00 . The company’s shares clo

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Alector (ALEC), with a price target of $29.00. The company's